RP-6306 manufacturers
- RP-6306
-
- $133.00
-
2026-07-27
- CAS:2719793-90-3
- Purity: 99.75%
- Supply Ability: 10g
|
| | RP-6306 Basic information |
| Product Name: | RP-6306 | | Synonyms: | RP-6306;2-amino-1-(3-hydroxy-2,6-dimethyl-phenyl)-5,6-dimethyl-pyrrolo[2,3-b]pyridine-3-carboxamide;1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, 2-amino-1-(3-hydroxy-2,6-dimethylphenyl)-5,6-dimethyl-, (1S)-;2-Amino-1-(3-hydroxy-2,6-dimethylphenyl)-5,6-dimethyl-7-azaindole-3-carboxamide;(1S)-2-Amino-1-(3-hydroxy-2,6-dimethylphenyl)-5,6-dimethyl-1H-pyrrolo[2,3-b]pyridine-3-carboxamide;RP-6306, 10 mM in DMSO;RP-6306 ，E1175;Iunresertib | | CAS: | 2719793-90-3 | | MF: | C18H20N4O2 | | MW: | 324.38 | | EINECS: | | | Product Categories: | | | Mol File: | 2719793-90-3.mol |  |
| | RP-6306 Chemical Properties |
| Boiling point | 489.2±45.0 °C(Predicted) | | density | 1.36±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO: Sparingly soluble: 1-10 mg/ml | | pka | 9.20±0.23(Predicted) | | form | Solid | | color | Off-white to gray | | InChI | InChI=1S/C18H20N4O2/c1-8-5-6-13(23)10(3)15(8)22-16(19)14(17(20)24)12-7-9(2)11(4)21-18(12)22/h5-7,23H,19H2,1-4H3,(H2,20,24) | | InChIKey | ARBRHWRTXPWZGN-UHFFFAOYSA-N | | SMILES | NC1=C(C2=CC(C)=C(C)N=C2N1C1C(=CC=C(O)C=1C)C)C(=O)N |
| | RP-6306 Usage And Synthesis |
| Uses | lunresertib (RP-6306) is a potent, selective and orally active PKMYT1 inhibitor with an IC50 of 14 nM. lunresertib shows a high degree of selectivity over other kinases in cellular binding assays. lunresertib shows anticancer effects[1]. | | in vivo | lunresertib (15, 50, and 300 ppm; oral; daily; for 21 days) results in a statistically significant and dose-dependent reduction in OVCAR3 tumor growth in CCNE1-amplified ovarian xenograft model (OVCAR3)[1]. | Animal Model: | OVCAR3-bearing mice[1] | | Dosage: | 15, 50, and 300 ppm (equivalent to approximately 3, 10, and 60 mg/kg/day) | | Administration: |
Oral; daily; for 21 days | | Result: | Resulted in a statistically significant and dose-dependent reduction in OVCAR3 tumor growth.
|
| | IC 50 | PKMYT1: 14 nM (IC50) | | References |
[1] Janek Szychowski, et al. Discovery of an Orally Bioavailable and Selective PKMYT1 Inhibitor, RP-6306. J Med Chem. 2022 Aug 11;65(15):10251-10284. DOI:10.1021/acs.jmedchem.2c00552
[2] David Gallo, et al. CCNE1 amplification is synthetic lethal with PKMYT1 kinase inhibition. Nature. 2022 Apr;604(7907):749-756. DOI:10.1038/s41586-022-04638-9
|
| | RP-6306 Preparation Products And Raw materials |
|